BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
BEGIN:VEVENT
DTSTAMP:20240328T220134Z
UID:9a64d9c8-1648-4da9-9b36-0e2e113ca329
DTSTART:20210208T080000
DTEND:20210209T080000
CLASS:PRIVATE
DESCRIPTION:
\n
\nImmuno-Oncology 360°\; is a c
omprehensive program providing exposure to the entire spectrum of R and D\
, addressing aspects from all facets of IO including:
\nDiscovery/Pre
clinical Science
\nTranslational Science
\nClinical Development<
br />\nBusiness Aspects
\nInvestor Relations
\nEmerging Technolo
gies
\nBiomarkers / Diagnostics
\nTrends in the Field
\n
\nLead Advisors Dr Axel Hoos\, GSK\, and Dr James Gulley\, NCI\, develo
ped the 4th annual IO360°\; program to include 45 speakers and over 30
talks. Dr Andrew Baum is the investor relations plenary keynote.
\n\nIO360°\; provides the most up-to-date research\, data and progres
s to help IO stakeholders:
\nBe at the forefront of relevant research
and developments from key leadership who are at the pulse of cancer immun
otherapy
\nFoster collaboration amongst those working in all aspects
of cancer immunotherapy together under one roof
\nReceive the late
st pre-clinical\, translational and clinical data from academic and indust
ry
\nGain a greater understanding of what assets are available for po
tential combinations  \;
\nCreate and prioritize strategies targe
ted toward specific tumor types
\nHear from IO clinical trial lead
ers as they cover trial design\, clinical operations\, the latest outcomes
and lessons learned
\nGet key investor and analyst evaluations and i
nsights on the IO landscape\, challenges and what&rsquo\;s next
\nHea
r reports on industry trends from Endpoint News and BioCentury Innovations
and a progress update on the Cancer Moonshot
\nLearn about biomarker
advancements in vaccines\, imaging\, neoantigen approaches and more
\nObtain coverage on a wide range of emerging technologies
\n
\n
Pharma and Biotech Special Rate:
\nTo support IO teams in drug develo
pment\, the registration fee for pharma and biotech companies includes a g
uest pass for a colleague from within the same company who has not yet att
ended IO360°\;. Guest pass must be claimed by Nov. 3\, 2021.
\n
\nEmail service@tcfllc.org for sponsorship and exhibitor opportunities.
\n
\nURL:
\nWebsite: https://go.evvnt.com/149446-1
\n
\nPrices:
\nPharma and Biotech starting rate: USD 1895\,
\nStandard Industry starting rate: USD 1895\,
\nAcademia\, Non-Pro
fit and Government starting rate: USD 947.50.
SUMMARY:Immuno-Oncology 360° 2021\, NYC
BEGIN:VALARM
ACTION:DISPLAY
TRIGGER:-PT1H
SUMMARY:Immuno-Oncology 360° 2021\, NYC
END:VALARM
END:VEVENT
END:VCALENDAR